Arch Biopartners Closes Non-Brokered Private Placement

Core Points - Arch Biopartners Inc. has closed a non-brokered private placement offering of 145,000 common shares at CAD $1.55 and 90,000 common shares at USD$1.15, totaling gross proceeds of CAD $374,000 [1][2] - The final amount of the offering increased by CAD$24,000 from the initial disclosure on March 5, 2025, and the proceeds will be used for general working capital and research expenses [2] - All common shares issued will be subject to a hold period of four months and one day from the closing date, with finders' fees totaling CAD $5,425 to be paid [3] Company Overview - Arch Biopartners Inc. is focused on preventing acute kidney injury and organ damage caused by inflammation, developing novel drugs targeting the dipeptidase-1 (DPEP1) inflammation pathway [4] - The company's lead drug candidates, LSALT peptide and cilastatin, aim to address significant unmet medical needs related to kidney injury caused by inflammation or toxins [4] - The company has 65,856,366 common shares outstanding [5]